Outcomes of primary refractory multiple myeloma and the impact of novel therapies
Author:
Affiliation:
1. Department of Internal Medicine; Mayo Clinic; Rochester Minnesota
2. Division of Hematology; Mayo Clinic; Rochester Minnesota
Funder
Mayo Clinic Hematological Malignancies Program
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24131/fullpdf
Reference45 articles.
1. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials;Myeloma Trialists' Collaborative Group.;J Clin Oncol,1998
2. VAD-based regimens as primary treatment for multiple myeloma;Alexanian;Am J Hematol,1990
3. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma;Dimopoulos;Ann Oncol,2003
4. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis of randomized controlled trials;Wang;Hematol Oncol,2012
5. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: A meta-analysis of phase III randomized controlled trials;Huang;Leuk Res,2014
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation;eJHaem;2024-06-16
2. High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy;American Journal of Hematology;2024-04-13
3. Time to progression predicts outcome of myeloma patients that can be influenced by autologous hematopoietic stem cell transplantation;2024-02-27
4. Microarray-Based CD38 Peptide Probe Screening for Multiple Myeloma Imaging;Molecular Pharmaceutics;2023-12-14
5. Aiming for the cure in myeloma: Putting our best foot forward;Blood Reviews;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3